Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-CellLymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standardof Care (SOC) Treatment (tx) from thePhase 3, Randomized Transform Study
Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-CellLymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standardof Care (SOC) Treatment (tx) from thePhase 3, Randomized Transform Study Stepan, L., Ansari, S., Okal, A., Dell'Aringa, J., Thompson, E. G., Crotta, A., Chow, V. A., Abramson, J. S., Kamdar, M., Solomon, S. R., Johnston, P. B., Glass, B., Mutsaers, P., Arnason, J. E., Mielke, S., Shadman, M., Hernandez-Ilizaliturri, F., Izutsu, K., Bachanova, S., Ibrahimi, S., Chabon, J., Kurtz, D., Alizadeh, A. A., Peiser, L. ELSEVIER. 2024: 72-74View details for DOI 10.1182/blood-2024-199813
View details for Web of Science ID 001410860600021